secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2026-08-14T20:30:49+00:00
Accession:  0001493152-26-038446
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma shareholders approve reverse stock split and incentive plan amendments
--------------------------------------------------------------------------------

- Approved reverse stock split (1-for-10 to 1-for-30) and cut authorized common to 25M, preferred to 1.5M.
- Elected directors Breen, Casamento, Kramer, Mun-Gavin; votes ranged 6.7M-8.1M for.
- Ratified Weinberg & Company as independent auditor for FY2026 (22.7M for).
- Approved non-binding executive compensation (6.1M for) and 2022 Plan amendments adding 3.5M shares and evergreen provision.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315226038446/0001493152-26-038446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315226038446/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-038446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer